GROTON, Conn. and RANDWICK, Australia, April 8, 2024 /7Newswire — The American maritime technology firm ThayerMahan, Inc. and Australian autonomous uncrewed vessel developer Ocius Technology Ltd announce they will collaborate to demonstrate a powerful new capability at the AUSVI XPONENTIAL event 23 to 25 April off San Diego. The collaboration places ThayerMahan’s Outpost system of acoustic sensors and …

Continue reading “ThayerMahan and Ocius Announce Collaboration and Demonstration at AUSVI XPONENTIAL off San Diego April 23-25”

SINGAPORE, April 7, 2024 /7Newswire — OKX, a leading Web3 technology company, has issued updates for April 7, 2024 OKX Wallet Now Integrated with SHUI, a Leading Liquid Staking Protocol OKX Wallet is now integrated with SHUI, a leading liquid staking protocol on Conflux. This integration enables eligible OKX Wallet users to access SHUI through the OKX Wallet …

Continue reading “Flash News: OKX Wallet Now Integrated with SHUI, a Leading Liquid Staking Protocol”

SHANGHAI, April 7, 2024 /7Newswire — Dizal (688192.SH) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations. This Breakthrough Therapy …

Continue reading “FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations”

DUBLIN, April 7, 2024 /7Newswire — Medtronic plc, a global leader in healthcare technology, today unveiled topline findings of its comprehensive survey on women’s perceptions and knowledge of risk factors, treatment patterns, and preventive care practices related to heart valve disease. The survey is endorsed by Women as One and was conducted by Wakefield Research sampling 1,000 …

Continue reading “New survey uncovers lack of awareness around heart valve disease and risk factors among women”

NEW YORK, April 7, 2024 /7Newswire — WHY: New York, N.Y., April 7, 2024. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) …

Continue reading “ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX”